Western Blot: SET Antibody [NBP1-30888] - Various whole cell extracts (30 ug) were separated by 12% SDS-PAGE, and the membrane was blotted with SET antibody, isoform 2-specifc diluted at 1:1000.
Immunocytochemistry/ Immunofluorescence: SET Antibody [NBP1-30888] - HeLa cells were fixed in 4% paraformaldehyde at RT for 15 min. Green: SET protein stained by SET antibody, isoform 2-specific diluted at 1:200. Red: ...read more
Immunohistochemistry-Paraffin: SET Antibody [NBP1-30888] - Paraffin-embedded A549 xenograft, using antibody at 1:100 dilution.
Western Blot: SET Antibody [NBP1-30888] - Whole cell lysate treated with SET Antibody, diluted at 1:1000 with 12% SDS PAGE ge.
Western Blot: SET Antibody [NBP1-30888] - Sample (30 ug of whole cell lysate) A: NIH-3T3 B: JC C: BCL-1 12% SDS PAGE; antibody diluted at 1:10000.
Western Blot: SET Antibody [NBP1-30888] - Sample (30 ug of whole cell lysate) A: Raji B: THP-1 12% SDS PAGE; antibody diluted at 1:10000.
Western Blot: SET Antibody [NBP1-30888] - Sample (30 ug of whole cell lysate) A: Hela 12% SDS PAGE; antibody diluted at 1:1000.
Immunocytochemistry/ Immunofluorescence: SET Antibody [NBP1-30888] - Paraformaldehyde-fixed HeLa, using antibody at 1:200 dilution.
33 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
SET belongs to a family of multitasking protein, involved in apoptosis, transcription, nucleosome assembly and histone binding. There are two named isoforms produced by alternative splicing : Isoform 1 and Isoform 2. Isoform 2 anti-apoptotic activity is mediated by inhibition of the GZMA-activated DNase, NME1. In the course of cytotoxic T-lymphocyte (CTL)-induced apoptosis, GZMA cleaves SET, disrupting its binding to NME1 and releasing NME1 inhibition. Isoform 1 and isoform 2 are potent inhibitors of protein phosphatase 2A. Isoform 1 and isoform 2 inhibit EP300/CREBBP and PCAF-mediated acetylation of histones (HAT) and nucleosomes, most probably by masking the accessibility of lysines of histones to the acetylases. The predominant target for inhibition is histone H4. HAT inhibition leads to silencing of HAT-dependent transcription and prevents active demethylation of DNA. Both isoforms stimulate DNA replication of the adenovirus genome complexed with viral core proteins; however, isoform 2 specific activity is higher. Isoform 1 and isoform 2 interact directly with each other and with ANP32A within the tripartite INHAT (inhibitor of acetyltransferases) complex. A chromosomal aberration involving SET is found in some cases of acute undifferentiated leukemia (AUL). Translocation t(6;9)(q21;q34.1) with NUP214/CAN.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
⚠ WARNING: This product can expose you to chemicals including mercury, which is known to the State of California to cause reproductive toxicity with developmental effects. For more information go to www.P65Warnings.ca.gov.
Publications for SET Antibody (NBP1-30888)(1)
We have publications tested in 1 confirmed species: Human.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.